目的 根据药物构效关系,设计合成出一系列结构新颖的V2受体拮抗剂,以期筛选出高效低毒的此类化合物,为进行下一步的临床前研究创造条件,为新药的创制奠定基础。方法 根据“me-too”的设计思路合成一定数量结构新颖的V2受体拮抗剂。通过核磁共振氢谱(1H-NMR)、高分辨质谱(HRMS)等手段进行结构确证,并且测定了熔点、纯度等相关理化常数。通过表达人类V2受体的细胞模型和大鼠利尿模型进行生物活性评价。结果 设计合成出12个未见文献报道的目标化合物(A1~A12),以托伐普坦为阳性对照药,其中A6,A7,A11等化合物表现出较强的生物活性,并且具有作用持续时间更长的特点。结论 化合物结构设计合理,对进一步开展V2受体拮抗剂的结构改造及其药理毒理活性研究具有一定的参考价值。
Abstract
OBJECTIVE To design and synthesize a series of novel V2 receptor antagonists according to the drug structure-activity relationship in order to screen out compounds with high efficacy and low toxicity and create conditions for preclinical research and lay foundation for the development of new drugs. METHODS A number of novel V2 receptor antagonists were synthesized according to the design idea of “me-too”. The structure was confirmed by 1H-NMR and HRMS, and the physicochemical constants related to the melting point and purity were determined. Biological activity was evaluated by cell model expressing human V2 receptor and rat diuretic model. RESULTS Twelve novel structural compounds(A1-A12) were designed and synthesized, among which A6, A7, A11 and other compounds showed strong biological activity and a longer duration of action than the existing V2 receptor antagonists. CONCLUSION The reasonable structure design of the compound has certain reference value for the further research on the structure modification of V2 receptor antagonist and their pharmacological and toxicological activities.
关键词
新型精氨酸加压素V2受体拮抗剂 /
结构设计 /
生物活性
{{custom_keyword}} /
Key words
novel arginine vasopressin V2 receptor antagonist /
structural design /
biological activity
{{custom_keyword}} /
中图分类号：
R914.2
{{custom_clc.code}}
({{custom_clc.text}})
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
[1] ADROGUé H J, MADIAS N E. Hypernatremia[J]. New Engl J Med, 2000, 342(20): 1493-1499.
[2] GHEORGHIADE M, ROSSI J S, COTTS W, et al. Characterization and prognostic value of persistent hyponatremia in patients with severe heart failure in the ESCAPE Trial[J]. Arch Internal Med, 2007, 167(18): 1998-2005,Doi:10.1111/j.1751-7133.2008.07773.x..
[3] ROSSI J, BAYRAM M, UDELSON J E, et al. Improvement in hyponatremia during hospitalization for worsening heart failure is associated with improved outcomes: insights from the Acute and Chronic Therapeutic Impact of a Vasopressin Antagonist in Chronic Heart Failure(ACTIV in CHF) trial[J]. Acute Cardiac Care, 2007, 9(2): 82-86.
[4] LANFEAR D E, SABBAH H N, GOLDSMITH S R, et al. Association of arginine vasopressin levels with outcomes and the effect of V2 blockade in patients hospitalized for heart failure with reduced ejection fraction clinical perspective insights from the EVEREST trial[J]. Circ: Heart Fail, 2013, 6(1): 47-52.
[5] GASSANOV N, SEMMO N, SEMMO M, et al. Arginine vasopressin(AVP) and treatment with arginine vasopressin receptor antagonists(vaptans) in congestive heart failure, liver cirrhosis and syndrome of inappropriate antidiuretic hormone secretion(SIADH)[J]. Eur J Clin Pharmacol, 2011, 67(4): 333-346.
[6] KONDO K, OGAWA H, YAMASHITA H, et al. 7-Chloro-5-hydroxy-1-[2-methyl-4-(2-methylbenzoylamino) benzoyl]-2, 3, 4, 5-tetrahydro-1 H-1-benzazepine(OPC-41061): A potent, orally active nonpeptide arginine vasopressin V 2 receptor antagonist[J]. Bioorg Med Chem, 1999, 7(8): 1743-1754.
[7] MARTINEZ-CASTELAO A. Lixivaptan(American home products)[J]. Curr Opin Investig Drugs, 2001, 2(4): 525-530.
[8] XIAO X, LI S S, TU L, et al. A retrospective study of tolaptan in the treatment of senile heart failure[J]. Chin J Hosp Pharm(中国医院药学杂志), 2019, 39(18):1881-1883.
[9] ARONSON J K, GREEN A R. Me-too pharmaceutical products: History, definitions, examples, and relevance to drug shortages and essential medicines lists[J]. Br J Clin Pharmacol, 2020, 21:1-9.
[10] LIU W, ZHOU J, ZHANG T, et al. Design and synthesis of thiourea derivatives containing a benzo [5, 6] cyclohepta [1, 2-6] pyridine moiety as potential antitumor and anti-inflammatory agents[J]. Bioorg Med Chem Lett, 2012,22(8):2701-2704.
[11] LIU G Z, XU H W, CHEN G W, et al. Stereoselective synthesis of desloratadine derivatives as antagonist of histamine[J]. Bioorg Med Chem, 2010, 18(4): 1626-1632.
[12] ALI F, RAUFI M A, WASHINGTON B, et al. Conivaptan: a dual receptor vasopressin v1a/v2 antagonist[J]. Cardiovasc Drug Rev, 2007, 25(3): 261-279.
[13] DAI Y Z. Progress in the diagnosis and treatment of heart failure [J]. Chin J Cardiovasc Dis(中华心血管病杂志), 2003, 31(9): 641-645.
[14] WANG K, ZHU T G, YU C, et al. Retrospectively analyzed of clinical characteristics and drug therapy of chronic heart failure in the elders[J]. Chin Pharm J(中国药学杂志), 2015, 50(10):901-904.
[15] MONDRITZKI T, KOLKHOF P, SABBAH H N, et al. Differentiation of arginine vasopressin antagonistic effects by selective V2 versus dual V2/V1a receptor blockade in a preclinical heart failure model[J]. Am J Ther, 2011, 18(1): 31-37.
[16] LIU X, ZHANG X Y, ZHAO Z G, et al. Advances in the treatment of hyponatremia by arginine vasopressin receptor antagonists[J]. Clin Med J, 2019, 10(17):24-27.
{{custom_fnGroup.title_cn}}
脚注
{{custom_fn.content}}
基金
国家科技重大专项“重大新药创制”课题资助(2013ZX09102104)
{{custom_fund}}
PDF(915 KB)
